As gene therapies advance toward indications with larger patient populations, adeno-associated virus (AAV) manufacturers are under growing pressure to deliver high-quality vectors at substantially ...
Gene therapies that are based on adeno-associated virus (AAV) vectors have demonstrated immense potential to treat and even cure previously intractable diseases, but unfortunately the costs are ...
Pharmaron Biologics, Liverpool, UK, is a commercial development and manufacturing organization (CDMO) that offers a range of unique end-to-end laboratory services for the development and manufacture ...
Leveraging Northway Biotech’s 20+ years of CDMO expertise, Diorasis Therapeutics is advancing AAV gene therapy for glaucoma treatment VILNIUS, LT / ACCESS Newswire / July 29, 2025 / Diorasis ...
HOLLISTER, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (TKNO), a leading producer of critical reagents for the research, discovery, development ...
Leveraging Northway Biotech’s 20+ years of CDMO expertise, Diorasis Therapeutics is advancing DT003, a single-dose AAV gene therapy for glaucoma. As part of the collaboration, Northway Biotech will ...
VILNIUS, LT / ACCESS Newswire / July 29, 2025 / Diorasis Therapeutics (“DTx”), a preclinical-stage biotechnology company developing gene therapies for ophthalmic diseases, has entered into a strategic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results